stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) Return on equity
Neurocrine Biosciences, Inc.'s return on equity over the twelve months to 30 September 2026 was 20.4%, up 4.0 percentage points from fiscal 2025 (16.4%). Over the past ten years it has ranged from −41.5% (fiscal 2017) to 46.2% (fiscal 2020); the current reading is higher than 91% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −0.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 16.4% | 2.22 |
| FY2024 | 14.2% | 1.48 |
| FY2023 | 12.7% | 2.65 |
| FY2022 | 10.0% | 2.86 |
| FY2021 | 7.17% | (39.03) |
| FY2020 | 46.2% | 39.58 |
| FY2019 | 6.62% | 1.67 |
| FY2018 | 4.95% | 46.45 |
| FY2017 | −41.5% | (3.33) |
| FY2016 | −38.2% | (10.08) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ZTS Zoetis Inc. compare | 64.9% |
| NBIX Neurocrine Biosciences, Inc. | 20.4% |
| UTHR United Therapeutics Corporation compare | 19.1% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 17.6% |
| RDY Dr. Reddy's Laboratories Ltd compare | 6.60% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| ALKS Alkermes plc compare | −0.02% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| VTRS Viatris Inc. compare | −4.21% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on NBIX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement